Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.…
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Black Diamond Therapeutics (NASDAQ: BDTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 21 employees.
The shares were at 1.310 USD on 20 November 2026, down 66.3% over 52 weeks. Its 52-week range is 1.310 USD to 4.940 USD, and it trades at the bottom of that range.
Its market capitalisation is 75.28M USD.
Black Diamond Therapeutics reports return on equity of 19.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 85.99M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. The next earnings report is expected on 15 March 2027.